NCEL
NewcelX Ltd.NASDAQHealthcare$2.25-5.10%ClosedMarket Cap: $1.0M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.30
P/S
0.00
EV/EBITDA
0.55
DCF Value
$10.09
FCF Yield
-500.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-101.0%
ROA
-49.9%
ROIC
-142.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-2.2M | $-10.50 |
| Q4 2024 | $0.00 | $55.0K | $-9.90 |
| FY 2024 | $0.00 | $-2.0M | $-26.30 |
| Q2 2024 | $0.00 | $-2.0M | $0.00 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell
Trading Activity
Insider Trades
View AllGalili Tamardirector
SellWed Mar 18
Twito Ronendirector, officer: Chairman and CEO
SellWed Mar 18
Revel Micheldirector, officer: CSO and Director
SellWed Mar 18
Revel Micheldirector, officer: CSO and Director
SellWed Mar 18
Hagai Omriofficer: Chief Financial Officer
SellWed Mar 18
Company Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NASDAQ
Beta
0.57
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.